New drug combo targets 'Undruggable' lung cancer
NCT ID NCT07307443
Summary
This study is testing a new combination treatment for people with a specific, hard-to-treat form of advanced lung cancer (SMARCA4-deficient). All participants will receive an oral pill called anlotinib alongside standard platinum-based chemotherapy. The main goals are to see if this combo can delay the cancer's growth longer than current options and to understand its side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMARCA4-DEFICIENT TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital
Beijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.